What changed
What changedBetween September 14 and September 29, 2026, Eli Lilly conducted several clinical trials, including studies of new compounds and the completion of a Phase 4 trial for diabetes treatment. These activities aim to assess the therapeutic potential of experimental agents and new indications for existing drugs.

Company history
October 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-10.
- 2026-10-08: Participants receive eloralintide subcutaneously as the experimental intervention. Source
- 2026-10-08: Participants receive single doses of LY4268989 in six treatment arms, with high‑fat and fasted states. Source
- 2026-10-08: The study enrolls 123 healthy participants and includes four inpatient stays at the clinical research unit. Source
- 2026-10-08: The study has four parts: single-ascending dose, multiple-ascending dose, single dose in three periods, and midazolam co‑administration. Source
- 2026-10-08: The trial is recruiting participants with overweight or prediabetic conditions to receive the investigational drug Orforglipron orally. Source
- 2026-10-08: Participants will receive LY4329090 administered subcutaneously (SC). Source
- 2026-10-08: The study includes two parts: Part A lasting about 10 weeks with 5 nights stay and 5 outpatient visits, Part B lasting about 21 weeks with 4 stays totaling 11 nights and 14 outpatient visits. Source
- 2026-10-08: The study is a randomized, parallel, double‑masked, basic science interventional study with estimated enrollment of 184 participants. Source
- 2026-10-08: The study will enroll 161 participants and is a Phase 2 randomized, open-label, parallel-design intervention study. Source
- 2026-10-08: The study will evaluate vepugratinib in adults with low‑grade, intermediate‑risk non‑muscle invasive bladder cancer or low‑grade upper tract urothelial carcinoma. Source
- 2026-10-09: The primary purpose of the study is basic science evaluating the safety and tolerability of LY5625575. Source
- 2026-10-09: The study will include healthy participants and participants with elevated high-sensitivity C-reactive protein. Source
September 2026
ELI LILLY & Co: 12 recorded developments from 7 official sources in 2026-09.
- 2026-09-23: The intervention includes abemaciclib in three formulations: Tablet Test Formulation 1, Oral Granules Test Formulation 2, and Reference Tablet Formulation 1. Source
- 2026-09-23: The trial will last about 8 weeks, including screening and follow-up. Source
- 2026-09-24: The trial is a phase 2, nonrandomized, sequential, open-label, single‑arm study of mosunetuzumab plus pirtobrutinib in relapsed or refractory Waldenstrom’s Macroglobulinemia. Source
- 2026-09-24: Patients must be ≥18 years with measurable Waldenstrom’s Macroglobulinemia and have relapsed or refractory disease after at least one prior line of therapy. Source
- 2026-09-24: The total number of cycles administered is 18 for patients with a complete, very good partial or minor response in dosing strategy 1 and 19 in dosing strategy 2. Source
- 2026-09-28: The trial is a prospective, single-arm, nonrandomized, open-label, phase I/II study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) in patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases. Source
- 2026-09-28: Treatment will be initiated with one week of abemaciclib followed by stereotactic radiation to sites of brain metastases or post-operative cavities with continued abemaciclib. Source
- 2026-09-28: The trial intervention included subcutaneous injections of insulin lispro-aabc (also known as LY900014 or Lyumjev) combined with insulin glargine (Basaglar). Source
- 2026-09-28: The company's product, baricitinib (Olumiant), was evaluated in a Phase 2 study for the treatment of central centrifugal cicatricial alopecia in adults of African descent. Source
- 2026-09-28: In a Phase 2 trial of baricitinib for central centrifugal cicatricial alopecia, 27 participants received at least one dose and 17 completed the 52-week treatment period. Source
- 2026-09-29: Eli Lilly and Company is conducting a Phase 1 study to evaluate the tolerability and side effects of the drug LY4057996 in healthy participants and those with Type 1 or Type 2 Diabetes. Source
- 2026-09-29: The study arms include experimental groups testing LY4057996 administered subcutaneously or intravenously, alone or in combination with other agents such as Lispro and basal insulin, against placebo and active comparators. Source
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
Sector peers
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Insider trades
| Date | Person | Trade | Shares | Avg. price | Value | Filing |
|---|
| November 2, 2026 | Anat Hakim | Sale 10b5-1 plan | 5,000 | $1,402.52 | $7,012,600 | SEC |
| October 30, 2026 | Lilly Endowment, Inc. | Planned sale | 295,000 | — | $405,241,500 | SEC |
| October 15, 2026 | Lilly Endowment, Inc. | Planned sale | 305,000 | — | $368,665,700 | SEC |
| October 7, 2026 | Lilly Endowment, Inc. | Planned sale | 300,000 | — | $347,247,000 | SEC |
All insider trades →
Large funds (13F)
| Fund | Shares | Value | Change in shares | Quarter |
|---|
| BlackRock | 67,936,153 | $78,607,563,355 | +0.6% | Q3 2026 |
| State Street | 36,848,565 | $42,636,737,590 | +1.7% | Q3 2026 |
| Fidelity (FMR) | 29,959,147 | $34,665,130,320 | +5.3% | Q3 2026 |
| Geode Capital Management | 20,556,572 | $23,722,722,425 | +1.2% | Q3 2026 |
| Capital Research Global Investors | 16,998,595 | $19,670,092,948 | -18.6% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 11,471,413 | $13,759,156,895 | — | Q2 2026 |
| Wellington Management | 11,048,493 | $12,783,990,282 | +0.5% | Q3 2026 |
| Citadel Advisors | 681,483 | $788,530,350 | -27.9% | Q3 2026 |
| Two Sigma Investments | 339,220 | $392,504,678 | +317.6% | Q3 2026 |
| D. E. Shaw & Co. | 316,379 | $366,075,814 | -36.3% | Q3 2026 |
| Millennium Management | 199,938 | $231,344,261 | +9.4% | Q3 2026 |
| ARK Investment Management (Cathie Wood) | 107,838 | $124,776,742 | +39.6% | Q3 2026 |
| Bridgewater Associates | 94,722 | $109,600,932 | +8.8% | Q3 2026 |
| Soros Fund Management | 22,199 | $25,686,019 | 0.0% | Q3 2026 |
| T. Rowe Price | 13,383,370 | $15,485,631 | -3.8% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.